Therapeutic potential of optimized derivatives of an endogenous CXCR4 antagonist for the treatment of cancers and inflammatory diseases

Project Information

EPI-X4Health

Grant agreement ID: 813081

DOI

10.3030/813081

Project closed

EC signature date 22 August 2018

Start date 1 September 2018

End date 29 February 2020

Funded under

• EXCELLENT SCIENCE - European Research Council (ERC)

Total cost

€ 149 156,00

EU contribution

€ 149 156,00

Coordinated by

UNIVERSITAET ULM
Germany

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Publications

Peer reviewed articles (1)

Microtiter plate-based antibody-competition assay to determine binding affinities and plasma/blood stability of CXCR4 ligands

Author(s): Mirja Harms, Andrea Gilg, Ludger Ständker, Ambros J. Beer, Benjamin Mayer, Volker Rasche, Christian W. Gruber, Jan Münch
Published in: Scientific Reports, Issue 10/1, 2020, ISSN 2045-2322
Publisher: Nature Publishing Group
DOI: 10.1038/s41598-020-73012-4